Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482969 | 0.81 | — | — | |
| SCHEMBL18214810 | 0.81 | — | — | |
| SCHEMBL14446900 | 0.78 | MAPT (0.36) | — | |
| SCHEMBL17544817 | 0.76 | — | — | |
| SCHEMBL2704159 | 0.75 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL21719542 | 0.73 | BRAF (0.31) | — | |
| SCHEMBL14383210 | 0.73 | HPGD (0.31) | — | |
| SCHEMBL21791914 | 0.73 | MEN1 (0.32) | — | |
| SCHEMBL2566954 | 0.73 | — | — | |
| SCHEMBL13314682 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| EP-4328225-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2021248231-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2021-12-16 | — | — | WO | disclosed |
| US-11178870-B2 | Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients | MITSUI CHEMICALS AGRO, INC. (JP) | 2021-11-23 | — | — | US | disclosed |
| US-11174254-B2 | Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-11-16 | — | — | US | disclosed |
| US-11155546-B2 | 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2021-10-26 | — | — | US | disclosed |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | REDX PHARMA LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| EP-2044055-A2 | AMIDE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| WO-2008011131-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249608-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249685-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | L3MBTL1 1001/4885 |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | L3MBTL1 1361/4885 |
| US-20070249608-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | L3MBTL1 1001/4885 |
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | L3MBTL1 3385/4885 |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | L3MBTL1 3270/4885 |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | L3MBTL1 919/4885 |
| US-11178870-B2 | Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients | PNPO, CYP4X1, PDXK | L3MBTL1 3199/4885 |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | PI4KA, IP6K3, PHOSPHO1 | L3MBTL1 3493/4885 |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | ROCK2, ROCK1, RHOA | L3MBTL1 3386/4885 |
| US-11155546-B2 | 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof | CYP2D6, DPYD, TPMT | L3MBTL1 4304/4885 |
| US-11174254-B2 | Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof | DPYD, ACR, QDPR | L3MBTL1 4496/4885 |
| US-20070249685-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | MUSK, CHUK, CAMK4 | L3MBTL1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.